Matthew Sykes
Stock Analyst at Goldman Sachs
(3.82)
# 601
Out of 4,865 analysts
205
Total ratings
50.7%
Success rate
7.68%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $5.46 | -8.42% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.19 | -5.96% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $10.56 | -38.45% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $37.62 | +19.62% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.98 | +60.64% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $33.92 | +41.51% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $10.95 | +55.25% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $141.86 | +12.79% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $6.99 | +43.06% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $94.16 | +32.75% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.15 | +6.46% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $195.75 | +22.61% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $19.52 | +33.20% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $145.05 | +17.20% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $49.53 | +13.06% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $64.04 | +24.92% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.30 | +15.38% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $167.55 | +13.40% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.73 | +140.05% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.09 | +103.35% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $26.76 | +38.27% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $52.54 | +23.72% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $154.10 | +62.23% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.14 | +290.88% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,150.57 | +12.99% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.55 | +40.35% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $390.26 | +63.99% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $116.09 | +24.90% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $46.55 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $5.46
Upside: -8.42%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.19
Upside: -5.96%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $10.56
Upside: -38.45%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $37.62
Upside: +19.62%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.98
Upside: +60.64%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $33.92
Upside: +41.51%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $10.95
Upside: +55.25%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $141.86
Upside: +12.79%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $6.99
Upside: +43.06%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $94.16
Upside: +32.75%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.15
Upside: +6.46%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $195.75
Upside: +22.61%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $19.52
Upside: +33.20%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $145.05
Upside: +17.20%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $49.53
Upside: +13.06%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $64.04
Upside: +24.92%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.30
Upside: +15.38%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $167.55
Upside: +13.40%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.73
Upside: +140.05%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.09
Upside: +103.35%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $26.76
Upside: +38.27%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $52.54
Upside: +23.72%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $154.10
Upside: +62.23%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.14
Upside: +290.88%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,150.57
Upside: +12.99%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.55
Upside: +40.35%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $390.26
Upside: +63.99%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $116.09
Upside: +24.90%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $46.55
Upside: -